Impact of skeletal-related events on survival in patients with metastatic prostate cancer prescribed androgen deprivation therapy

Wong, Kai Pun; Ma, WK; Wong, CW; Wong, Michael; Tsang, Chi‐Ching; Tsu, HL; Ho, KL; Yiu, MK

doi:10.12809/hkmj144449

Cited by 11 publications

(9 citation statements)

References 38 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Presence of BMs was associated with lower 2-year OS compared to men with soft-tissue metastases, from 85% to 60% (HR: 3.42), and the presence of BMs (regardless of visceral spread) was shown to be associated with worse failure-free survival (FFS) and OS in multivariate analysis 65. Wong et al 66. also studied the impact of SRE on survival in patients with metastatic PCa undergoing ADT.…”

Section: Systemic Treatment Of Bmsmentioning

confidence: 99%

Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer

Hegemann¹,

Maas²,

Rausch³

et al. 2019

Asian J Androl

View full text Add to dashboard Cite

Bone metastases have a major impact on quality of life and survival of patients with advanced prostate cancer. In the last decade, the development and approval of substances inhibiting the vicious cycle of bone metastases have enabled the reduction of complications caused by bone metastases in patients with castration-resistant prostate cancer. These drugs have raised awareness of the importance of skeletal-related events which in the meantime represent an important end point also in trials using agents not specifically designed for bone lesions. Second-generation antihormonal drugs such as enzalutamide or abiraterone have been shown to have a positive impact on the incidence of skeletal complications and therefore provide an important tool in the armamentarium used for treating bone metastases. Radiopharmaceuticals such as radium-223 dichloride ([223Ra]) have been demonstrated not only to reduce skeletal-related events and bone-related pain, but also to prolong overall survival, thereby being the first bone-targeting agent showing a survival benefit. As previous studies have not provided an obvious benefit of bone-targeted lesions in castration-sensitive disease, the use of these agents is not recommended. In oligometastatic prostate cancer, the role of local treatment of metastases using stereotactic radiation or radiosurgery is a matter of intense debates and may play an increasing role in the future.

show abstract

Section: Systemic Treatment Of Bmsmentioning

confidence: 99%

Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer

Hegemann¹,

Maas²,

Rausch³

et al. 2019

Asian J Androl

View full text Add to dashboard Cite

show abstract

“…Despite no definite survival advantages, zoledronic acid and denosumab can reduce the risk of skeletal‐related events in patients with mCRPC . As shown in a cohort study conducted in Hong Kong, skeletal‐related events could worsen the prognosis of patients with mCRPC in terms of OS and cancer‐specific survival . In this regard, among patients with mCRPC with bone metastases, zoledronic acid or denosumab can be considered for prevention of skeletal‐related events.…”

Section: Resultsmentioning

confidence: 99%

Consensus statements on the management of metastatic prostate cancer from the Hong Kong Urological Association and Hong Kong Society of Uro‐Oncology

Poon

Chan

et al. 2018

BJU International

View full text Add to dashboard Cite

To establish a set of consensus statements to facilitate physician management strategies for patients with metastatic prostate cancer (mPCa) in Hong Kong. A local expert consensus was organized jointly by the two main professional organizations representing prostate cancer specialists in Hong Kong. A total of 12 experts were included in the consensus panel. Six of the most crucial and relevant areas of debate regarding the management of mPCa were identified. With the use of a modified Delphi method, several panel meetings were held for the members to discuss their clinical experience and the published literature relevant to the areas of debate. At the final meeting, each drafted statement was voted on by every member based on its practicability of recommendation in the locality. After the panel voting, a total of 45 consensus statements regarding the management of mPCa were ultimately accepted and established. The consensus statements were primarily derived from the latest clinical evidence and major overseas guidelines, with the consideration of local clinical experience and practicability. These are considered applicable recommendations for Hong Kong physicians for the management of mPCa patients.

show abstract

“…Organconfined prostate cancer at the time of diagnosis is associated with a good prognosis and a favourable response to curative therapy [24]. Conversely, metastatic prostate cancer is associated with a poor prognosis, and skeletal metastasis is associated with a 5-year survival rate of <30% [25].…”

Section: Discussionmentioning

confidence: 99%

Positron emission tomography/computed tomography-guided percutaneous trans-pararectal space prostate biopsy for the diagnosis of prostate cancer: A retrospective study

Luo

Ruan

Pang

et al. 2019

Preprint

View full text Add to dashboard Cite

Oncology 2 KEYWORDS positron emission tomography/computed tomography, prostate cancer, percutaneous trans-pararectal space prostate biopsy Abstract Background: Biopsy is considered the gold-standard technique for prostate cancer diagnosis and is recommended in patients with a high clinical indication of prostate cancer. In this study, we aimed to determine the diagnostic efficacy of a novel positron emission tomography (PET)/computed tomography (CT)-guided percutaneous trans-pararectal space-based approach to targeted prostate biopsy. Methods: PET/CT-guided percutaneous trans-pararectal space prostate biopsies were performed in 14 consecutive patients with indications of prostate cancer. Whole-body 18F-FDG PET/CT indicated the presence of 18F-fluorodeoxyglucose (FDG)-avid focal prostate lesions. Two tissue specimens were obtained from each patient. The final diagnoses were established based on the results of a histopathological analysis and clinical follow-up, and these findings were used to verify the diagnostic accuracy of 18F-FDG PET/CT for prostate cancer. Results: The diagnostic accuracy of 18F-FDG PET/CT for prostate cancer was 81.8%. Further analyses of the two biopsied samples per patient led to confirmed histopathological and immunohistochemical diagnoses of prostate cancer in all 14 patients. Consequently, the success rate of PET/CT-guided percutaneous trans-pararectal space prostate-targeted biopsy for the diagnosis of prostate cancer was 100.0% (14/14). Regarding safety, the average duration of biopsy was 20 min, and no serious complications occurred.Conclusions: PET/CT-guided percutaneous trans-pararectal space prostate biopsy may yield a new approach to targeted prostate biopsy for the diagnosis of prostate cancer. Moreover, this biopsy procedure can be performed safely without complications, and is more cost-effective than conventional trans-rectal and trans-perineal prostate biopsy methods.

show abstract

Impact of skeletal-related events on survival in patients with metastatic prostate cancer prescribed androgen deprivation therapy

Cited by 11 publications

References 38 publications

Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer

Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer

Consensus statements on the management of metastatic prostate cancer from the Hong Kong Urological Association and Hong Kong Society of Uro‐Oncology

Positron emission tomography/computed tomography-guided percutaneous trans-pararectal space prostate biopsy for the diagnosis of prostate cancer: A retrospective study

Contact Info

Product

Resources

About